Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Crosswalk Therapeutics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This application is being reviewed by examiner CHOWDHURY, IQBAL HOSSAIN, the distinct examiner for the portfolio. The matter is assigned to a distinct art unit, and CHOWDHURY, IQBAL HOSSAIN holds the busiest examiner pending count of 1.
This focus means that the outcome of the current prosecution depends on the interpretation of an individual within a specific technical department. For a practitioner, this environment suggests that building a consistent rapport with CHOWDHURY, IQBAL HOSSAIN is a primary factor in navigating the USPTO. The absence of multiple distinct examiners or art units reduces the complexity of tracking various examiner preferences. Consequently, the company's immediate patent strategy is tied to the progress of this individual application. The concentrated nature of the portfolio allows for a streamlined approach to addressing any technical rejections within the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHOWDHURY, IQBAL HOSSAIN | 1 | 73.6% | +57.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18759313 | ENGINEERED ACID ALPHA-GLUCOSIDASE VARIANTS | CHOWDHURY, IQBAL HOSSAIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18759313 | ENGINEERED ACID ALPHA-GLUCOSIDASE VARIANTS | CHOWDHURY, IQBAL HOSSAIN | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18759313 | ENGINEERED ACID ALPHA-GLUCOSIDASE VARIANTS | CHOWDHURY, IQBAL HOSSAIN | 1656 | §102§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCrosswalk Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Iqbal Hossain Chowdhury has the most, with 1 of Crosswalk Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
